HMOX1 and colorectal carcinoma: The research has explained that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells as well as RSL3-induced ferroptosis by activating p38 MAPK and inhibiting the Nrf2/HO-1 pathway [77].